Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
2024年9月23日 - 8:00PM
Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic
medicines company focused on improving the lives of patients with
neurodegenerative diseases, today announced that Will Chou, M.D.,
president and chief executive officer, will present at Chardan’s
8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024
at 8:30 a.m. ET.
A live webcast of the event will be available on the Investors
& Media section of Passage Bio’s website at
investors.passagebio.com. A replay of the presentation will be
available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines
company on a mission to improve the lives of patients with
neurodegenerative diseases. Our primary focus is the development
and advancement of cutting-edge, one-time therapies designed to
target the underlying pathology of these conditions. Passage Bio’s
lead product candidate, PBFT02, seeks to treat neurodegenerative
conditions, including frontotemporal dementia, by elevating
progranulin levels to restore lysosomal function and slow disease
progression.
To learn more about Passage Bio and our steadfast commitment to
protecting patients and families against loss in neurodegenerative
conditions, please visit: www.passagebio.com.
For further information, please contact:
Investors:Stuart HendersonPassage
Bio267.866.0114shenderson@passagebio.com
Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502mikebeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
過去 株価チャート
から 10 2024 まで 11 2024
Passage Bio (NASDAQ:PASG)
過去 株価チャート
から 11 2023 まで 11 2024